Ardaman Shergill to Rectal Neoplasms
This is a "connection" page, showing publications Ardaman Shergill has written about Rectal Neoplasms.
Connection Strength
1.169
-
Utilizing Patient Input in Rectal Cancer Trial Design. J Natl Cancer Inst. 2025 Jul 01; 117(7):1421-1428.
Score: 0.211
-
Diagnostic Challenges due to a Germline Missense MSH2 Variant in a Patient With Immunotherapy-Responsive Locally Advanced Rectal Adenocarcinoma. Cancer Rep (Hoboken). 2024 Dec; 7(12):e70037.
Score: 0.203
-
Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer. BMC Cancer. 2024 Jul 26; 24(1):901.
Score: 0.198
-
Alliance for clinical trials in Oncology (Alliance) trial A022101/NRG-GI009: a pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur). BMC Cancer. 2024 Feb 13; 24(1):201.
Score: 0.192
-
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023 07 01; 402(10395):41-53.
Score: 0.183
-
Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med. 2023 07 27; 389(4):322-334.
Score: 0.183